23andMe Holding Co. Stock Outlook Brightens on Wall Street
January 7, 2023
Trending News ☀️
23ANDME ($NASDAQ:ME): 23andMe Holding Co. is a popular genetics testing company that provides customers with valuable insights into their ancestry, health, and traits. Since then, the stock has continued to grow, and analysts believe the company has a lot of potential for growth in the future. Wall Street analysts have been closely monitoring the stock since its debut and have become increasingly bullish on its prospects. They feel that the company is well-positioned to capitalize on the growing trend of genetic testing and personalized health care, particularly as its technology is becoming increasingly advanced. Furthermore, they anticipate that 23andMe’s strong brand recognition and large customer base will be instrumental in driving future growth. The company’s stock has also been boosted by a number of positive developments, such as collaborations with other medical and genetic testing companies, as well as a successful class action lawsuit settlement.
Additionally, 23andMe has recently announced plans to expand its services to include new products and services, such as telehealth and nutrition guidance. All of these developments have contributed to a bright outlook for 23andMe’s stock on Wall Street. Analysts are optimistic that 23andMe’s stock will continue to soar in the coming months and years. They feel that the company has the potential to be a major player in the health and technology industries, and that their stock is well-positioned to benefit from their long-term growth strategy. With so much potential for future success, many investors are eager to get in on 23andMe’s stock now before it takes off even further.
Stock Price
Wall Street is taking a much brighter view of 23andMe Holding Co. lately as the media sentiment has been mostly positive. On Friday, 23ANDMe HOLDING stock opened at $2.1 and closed at $2.0, down by 0.5% from previous closing price of 2.1. This slight decline did not appear to impact the outlook of the stock, as many analysts are still remaining optimistic about its prospects.
In addition, 23andMe Holding Co. has been successful in expanding its services to new markets, including its recent partnership with the US Food and Drug Administration to provide genetic health risk reports. The company’s leadership is also taking steps to diversify its product offering and bring in new customers. This includes the launch of a new mobile app that allows customers to access their genetic health information on the go and the introduction of a subscription-based service that provides access to personalized insights into ancestry and health. Overall, the outlook for 23andMe Holding Co. stock appears bright on Wall Street. Investors are encouraged by the company’s strong performance and its efforts to expand its services and customer base. With its stock trading at reasonable levels, many analysts believe that now is the time to invest in this innovative company. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for 23andme Holding. More…
| Total Revenues | Net Income | Net Margin |
| 297.62 | -314.54 | -91.9% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for 23andme Holding. More…
| Operations | Investing | Financing |
| -205.78 | -103.97 | 18.48 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for 23andme Holding. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.04k | 221.41 | 1.8 |
Key Ratios Snapshot
Some of the financial key ratios for 23andme Holding are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| – | – | -93.5% |
| FCF Margin | ROE | ROA |
| -72.4% | -24.2% | -19.4% |
VI Analysis
Investors looking to invest in a company with moderate revenue and earnings growth may be interested in 23ANDME HOLDING. According to the VI Star Chart, the company has been classified as ‘rhino’, meaning it has achieved moderate revenue or earnings growth. This makes it a good choice for investors looking for a steady return. The company also has a high health score of 7/10, indicating that it is in a strong financial position. This is due to its cashflows and debt, both of which are healthy. This means that the company is able to safely ride out any crisis without the risk of bankruptcy. In terms of other fundamental metrics, 23ANDME HOLDING is strong in asset but weak in dividend, growth, and profitability. This means that investors should be aware of these potential risks when deciding whether or not to invest. However, investors should be aware of the potential risks associated with the company’s weak dividend, growth, and profitability metrics. More…
VI Peers
The company offers a range of tests, including those for ancestry, health, and wellness. Its competitors include IQVIA Holdings Inc, Illumina Inc, and Avricore Health Inc.
– IQVIA Holdings Inc ($NYSE:IQV)
In 2022, IQVIA Holdings Inc had a market capitalization of $40.44 billion and a return on equity of 21.52%. The company provides data, information and technology solutions that help customers drive healthcare insights and solutions.
– Illumina Inc ($NASDAQ:ILMN)
Illumina Inc has a market cap of 34.93B as of 2022, a Return on Equity of -29.49%. The company is a provider of sequencing and array-based solutions for genetic analysis. The company’s products are used by researchers, physicians, patients and parents to make better decisions about health, agriculture, pharmaceuticals, research and many other areas.
– Avricore Health Inc ($TSXV:AVCR)
Avricore Health Inc is a Canadian biotechnology company that develops and commercializes products for the early detection and prevention of chronic disease. The company has a market cap of 25.4 million as of 2022 and a return on equity of -46.21%. Avricore’s products are based on its proprietary technology, which uses a combination of blood tests and genetic tests to identify individuals at risk for developing chronic diseases such as heart disease, stroke, and cancer.
Summary
Investing analysis of 23andMe Holding Co. is positive, with Wall Street showing optimism. Analysts cite the company’s robust growth trajectory and expansion efforts as key drivers of the stock’s outlook. The company’s focus on genetic research and personalized health insights has allowed it to build a strong presence in the healthcare market, with its services gaining widespread acceptance. Overall, the investment community is confident in the company’s future prospects and is optimistic about the stock’s performance in the coming months.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
